Cancer Biotherapy and Radiopharmaceuticals

Editor-in-Chief: Martin W. Brechbiel, PhD

ISSN: 1084-9785 | Online ISSN: 1557-8852 | 10 Issues Annually | Current Volume: 37

Impact Factor: 3.099 2020 Journal Citation Reports (Clarivate, 2021)

CiteScore™: 3.5

The definitive source for peer-reviewed research on cutting-edge therapeutic investigations and advancements in radioimmunotherapy for treating cancer.

Search Subscribe/Renew Recommend This Title Sign Up for TOC Alerts View Submission Instructions Share with a Colleague

News Releases

Friday, August 3, 2018

What Role Do Inflammatory Cytokines Play In Creating T Cell Exhaustion in Cancer?

Monday, August 28, 2017

Designing Novel Biologic Agents to Target Colorectal Cancer

Friday, October 14, 2016

Long-Term Experience Supports Efficacy and Safety of PRRT for Treating Neuroendocrine Tumors

Tuesday, May 10, 2016

Long-Term Survival Achieved in Metastatic Melanoma With Personalized Vaccine

Monday, April 6, 2015

Can Cancer Vaccines Prolong Survival?

Monday, November 12, 2012

Can the Addition of Radiolabeled Treatments Improve Outcomes in Advanced Metastatic Disease?

Thursday, July 26, 2012

Should High-Dose Interleukin-2 Continue to be the Treatment of Choice for Metastatic Melanoma?

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.